Structure via PubChem · Public domain (PubChem)
ruboxistaurin
Sign in to saveAlso known as LY-333531
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
In the Vinony graph
Within Vinony's link graph, ruboxistaurin is referenced by 3 other articles, and connects out to medication, digital object identifier and chemical formula.
Vinony files it under Abandoned drugs, Bisindolylmaleimides and Chemical pages without DrugBank identifier.
Its subject is documented across 4 Wikipedia language editions.
Chemical data
- Formula
- C28H28N4O3
- Molecular weight
- 468.5 g/mol
- IUPAC name
- (18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.17,14.02,6.08,13.022,27]nonacosa-1(28),2(6),7(29),8,10,12,22,24,26-nonaene-3,5-dione
- SMILES
- CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
- InChIKey
- ZCBUQCWBWNUWSU-SFHVURJKSA-N
- XLogP
- 2.7
- Polar surface area
- 68.5 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- diabetic retinopathy, diabetes mellitus, heart failure, diabetic neuropathy
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 468.216
Show 5 more facts
- chemical formula
- C₂₈H₂₈N₄O₃
- canonical SMILES
- CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
- isomeric SMILES
- CN(C)C[C@@H]1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
- subject has role
- enzyme inhibitor
- Commons category
- Ruboxistaurin
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
3 sectionsContents
- Mechanism of action
- References
- External links
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
In February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an approvable letter from the US FDA for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete. Lilly has not made any further request for approval and ruboxistaurin is not approved by the FDA for any medical use.
Excerpted from Wikipedia’s “ruboxistaurin” article, available under the CC BY-SA 4.0 licence.